Physician profile
Grace Mclaurin
NPI 1366441149
$553,258.53
in general payments reported to CMS, 2019-2025
9 companies · $110K in 2025
The $110K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $105K · 2022: $137K · 2023: $116K · 2024: $86K · 2025: $110K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $283K · Travel and Lodging: $21K · Food and Beverage: $4,654 · Consulting Fee: $2,613 · Education: $33.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $282,803.56 |
| Travel and Lodging | $20,937.02 |
| Food and Beverage | $4,653.70 |
| Consulting Fee | $2,613.00 |
| Education | $33.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $241,683.57 | 2021-2022 | |
| Galderma Laboratories, L.P. | $194,207.45 | 2021-2025 | Dysport |
| Abbvie INC. | $99,034.24 | 2023-2025 | |
| Revance Therapeutics, INC. | $17,990.75 | 2024-2025 | Daxxify |
| Currax Pharmaceuticals LLC | $141.20 | 2021-2022 | |
| Merz North America, INC. | $98.16 | 2022-2025 | |
| Musculoskeletal Transplant Foundation INC. | $68.35 | 2021 | |
| Avion Pharmaceuticals | $19.37 | 2022 | |
| Novo Nordisk INC | $15.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Mclaurin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.